Integration of optical genome mapping and transcriptomic RNA sequencing has resolved a structurally complex de novo gene duplication in the ASH1L gene, reclassifying a previously ambiguous variant as a likely pathogenic loss-of-function mutation in a 15-year-old male evaluated for autism spectrum disorder.
Copy number variants, comprising gains and losses of genomic segments, represent a frequent etiology of genetic disorders. While full gene duplications preserve the coding transcript sequence and typically alter expression levels without disrupting protein architecture, partial gene duplications present far greater interpretive difficulty. These structural alterations can occur in direct or inverted orientations and insert either in tandem adjacent to the donor locus or interspersed across distant genomic regions. Partial intragenic tandem duplications that encompass coding exons are particularly impactful because they can duplicate coding DNA sequences, generating in-frame protein extensions or introducing frameshifts that create premature termination codons and induce haploinsufficiency.
Standard molecular diagnostic workflows, including array comparative genomic hybridization and exome sequencing, frequently fail to resolve the comprehensive physical structure and transcriptional repercussions of partial gene duplications. To overcome these diagnostic blind spots, long-fragment physical analysis technologies, such as optical genome mapping based on ultra-high-molecular-weight DNA molecules, provide long-range structural scaffolding capable of delineating complex genomic architecture.
The clinical subject of the investigation was a 15-year-old male referred for etiological evaluation of autism spectrum disorder. Born eutrophic at 38 weeks of gestation following a pregnancy complicated by maternal hypertension and intrapartum fetal heart rate abnormalities, the patient weighed 3,920 grams, measured 51.5 centimeters in length, and presented an occipitofrontal head circumference of 36.5 centimeters. Early neonatal examinations identified plagiocephaly and a clavicular fracture but were otherwise unremarkable. Although initial motor milestones fell within expected timeframes, including attaining unassisted sitting at eight to nine months and independent walking at eleven months, the boy later manifested a complex oral and written language disorder necessitating speech therapy, alongside persistent sleep disruption dating from infancy.
As the patient progressed through standard schooling with dedicated life assistant support, comprehensive behavioral evaluations documented severe interaction challenges, generalized anxiety, attention deficit hyperactivity disorder, motor and oral tics, hyperphagia, and behavioral peculiarities that culminated in a formal diagnosis of autism spectrum disorder via the Autism Diagnostic Observation Schedule. Physical and neurological examinations noted an absence of facial dysmorphisms, accompanied by bilateral myopia and astigmatism, Wechsler Intelligence Scale for Children subscores between 71 and 83, and electroencephalography displaying polyspikes and waves without overt seizures. Family pedigree assessment revealed an asymptomatic maternal half-sister, an asymptomatic father, and a mother affected by HLA-B27-positive ankylosing spondylitis with a history of three miscarriages. An older brother had also received diagnoses of mild autism spectrum disorder and intellectual disability, but exhibited a distinct phenotype characterized by triangular fingers, anteverted nostrils, and attached earlobes.
Diagnostic genomic exploration commenced with array comparative genomic hybridization using an Agilent 180K platform, which identified a 199-kilobase interstitial heterozygous duplication on the long arm of chromosome 1, spanning coordinates 1q22(155,253,465_155,452,974)x3. Universal digital polymerase chain reaction assays confirmed the copy number gain, while microsatellite marker analyses established that the variant arose de novo, being absent in both parents and the affected sibling. The duplicated genomic segment encompassed eight non-disease-associated genes and overlapped the terminal portion of ASH1L from exon 4 through its 3 prime extremity. Subsequent exome sequencing on an Illumina NovaSeq 6000 confirmed a single duplication spanning coordinates 1q22(155,234,977_155,459,950) but detected no additional pathogenic or likely pathogenic variants capable of explaining the clinical presentation.
To elucidate the physical architecture of the rearrangement, the investigators performed optical genome mapping utilizing the Bionano Genomics Saphyr platform. Ultra-high-molecular-weight genomic DNA was extracted from whole peripheral blood leukocytes using nanobind disk technology. Intact DNA molecules ranging from 150 kilobases to several megabases were enzymatically labeled at specific CTTAAG motif sites occurring approximately every six kilobases throughout the human genome using the Direct Label Enzyme DLE-1 and DL-green fluorophores.
De novo optical assembly revealed that the single 199-kilobase event was in fact a complex compound rearrangement composed of two separate, contiguous tandem duplications at 1q22. The first rearrangement was a large 135-kilobase tandem duplication spanning exons 7 through 23 of ASH1L along with six downstream genes. Adjacent to this event, optical genome mapping resolved a previously undetected second rearrangement: a 47-kilobase intragenic tandem duplication encompassing exons 4, 5, and 6 of ASH1L. This smaller intragenic duplication disrupted the reading frame of the transcript, introducing a frameshift and a downstream premature stop codon. Because ASH1L causes an autosomal dominant neurodevelopmental syndrome through haploinsufficiency, this precise structural elucidation permitted clinicians to reclassify the variant from uncertain significance to likely pathogenic.
To confirm whether the predicted frameshift altered transcript maturation, the team conducted transcriptomic RNA sequencing on peripheral blood. Total RNA isolated from Paxgene blood tubes underwent reverse transcription and exonic capture prior to sequencing on an Illumina NextSeq 500 system, with read alignment and transcript quantification executed via the nf-core pipeline using STAR, Salmon, and RSeQC. Analysis of aligned BAM files using the Integrative Genomics Viewer confirmed the presence of aberrant transcripts containing aberrant exon 6 to exon 4 junctions, which accounted for approximately 50 percent of the reads spanning that region. Exon-level expression quantification further demonstrated a two-fold elevation in messenger RNA abundance specifically across duplicated exons 4 through 6, verifying transcriptional activity from the mutant allele.
Unexpectedly, overall quantification of ASH1L expression indicated normal global messenger RNA levels, showing transcripts per million values within the exact distribution observed across twelve matched control samples. This finding demonstrated that despite carrying a frameshift and premature termination codon, the aberrant transcript failed to trigger degradation by the nonsense-mediated mRNA decay machinery. The authors noted that unadjusted bulk quantification counts reads from duplicated exons toward total gene abundance, potentially obscuring reduced expression of non-duplicated exons. Mechanistically, this escape from degradation may stem from tissue-specific variations in nonsense-mediated decay efficiency in blood, alternative splicing events that excise susceptible exonic segments, or structural features preventing exon junction complex deposition.
The findings highlight the diagnostic precision gained by integrating optical genome mapping with transcriptomic validation when evaluating de novo structural variants of uncertain clinical consequence. While optical genome mapping successfully resolved breakpoints obscured during short-read exome and microarray analysis, the authors observed that all molecular technologies face inherent constraints in genomic regions enriched with dense segmental duplications or repetitive centromeric heterochromatin. Nevertheless, the study underscores optical genome mapping as an accessible, mature diagnostic modality that refines variant interpretation and clarifies mechanisms of developmental pathogenicity pending wider clinical deployment of long-read genome sequencing technologies.
Subject of Research: Resolution and transcriptomic characterization of a complex de novo ASH1L gene duplication using optical genome mapping and RNA sequencing
Article Title: Revealing the impact of partial gene duplications in ASH1L: integration of optical genome mapping and RNA sequencing
Article References: Blavier, G., Lecoquierre, F., Guerrot, A.-M., Hélas, G. J., Rondeau, S., Boland, A., Deleuze, J.-F., Nicolas, G., Chambon, P., & Cassinari, K. (2025). Revealing the impact of partial gene duplications in ASH1L: integration of optical genome mapping and RNA sequencing. Molecular Cytogenetics, 19(1), Article 2. https://doi.org/10.1186/s13039-025-00740-5
Image Credits: AI Generated
DOI: 10.1186/s13039-025-00740-5
Keywords: optical genome mapping, RNA sequencing, ASH1L gene, partial gene duplication, autism spectrum disorder, structural variants, copy number variants, nonsense-mediated decay, intragenic duplication, array CGH, exome sequencing, Bionano Genomics, loss of function, neurodevelopmental disorders, chromosome 1q22, haploinsufficiency
News Source: Juliet Wilcox. (November 21, 2026). Optical Genome Mapping Resolves Complex ASH1L Duplication in Autism Spectrum Disorder. Scienmag.



